Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 31, 2009

View Archived Issues

Budesonide fails to prevent ipilimumab-induced diarrhea in advanced melanoma patients

Dainippon Sumitomo Pharma reports results from Q1 ending June 30, 2009

Novel MAP kinase p38 inhibitor effective in rat models of arthritis

Novel GlaxoSmithKline agents activate SIRT1

Bayer describes novel phosphatidylinositol 3-kinase inhibitors

French scientists disclose bisphosphonate-based vectors for targeting bone tissue

Orexo and Novartis sign exclusive worldwide licensing agreement for OX-17-related product

Arno initiates dosing in phase I clinical study of PDK1 inhibitor AR-12 in cancer

Biotie Therapies reaches milestone in Wyeth collaboration for PDE10 inhibitors for schizophrenia

Clinical trials of GAI-122 for prevention of delirium expected to begin by mid-2010

IDRI initiates phase I clinical trial of leishmaniasis vaccine candidate

Hisamitsu acquires Noven

Taisho developing mGlu5 receptor antagonists for anxiety

Novel ZAP-70 inhibitors reported to be in early development at Cellzome

Dainippon Sumitomo Pharma patents DPP IV inhibitors for diabetes

REG1 system induces controlled anticoagulation in phase IIa study in PCI patients

Research collaboration identifies possible new treatments for human African trypanosomiasis

Compounds inhibiting PI3 kinase designed by Wyeth for treating cancer

Facet Biotech and Trubion sign collaboration agreement for TRU-016 in CLL

Innate Pharma granted approval to initiate phase IIa trial of IPH-2101 for multiple myeloma

Health Canada approves Medicago's CTA for phase I human clinical trial of H5N1 vaccine

Takeda initiates EXAMINE cardiovascular outcomes trial of alogliptin for diabetes

Stallergenes names second sublingual desensitization tablet

Valcyte approved for prevention of CMV in pediatric transplant patients

RE-LY study reveals advantage of dabigatran over warfarin in atrial fibrillation patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026